Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 173,200 shares, a decline of 34.5% from the September 30th total of 264,400 shares. Based on an average daily volume of 553,300 shares, the short-interest ratio is presently 0.3 days. Approximately 0.8% of the company’s stock are short sold. Approximately 0.8% of the company’s stock are short sold. Based on an average daily volume of 553,300 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ENLV. D. Boral Capital reissued a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Enlivex Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Enlivex Therapeutics to a “sell” rating in a research report on Saturday, August 30th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. Citizens Financial Group Inc. RI purchased a new stake in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 231,424 shares of the company’s stock, valued at approximately $241,000. Citizens Financial Group Inc. RI owned 0.95% of Enlivex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Stock Performance

Enlivex Therapeutics stock remained flat at $1.05 during mid-day trading on Monday. 80,214 shares of the company’s stock were exchanged, compared to its average volume of 243,511. The company has a market capitalization of $25.51 million, a price-to-earnings ratio of -1.81 and a beta of 0.90. The firm’s fifty day moving average is $1.07 and its 200 day moving average is $1.11. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.10.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.